A medical device manufacturer discovers a recurring nonconformity during in-process testing of a Class II device. According to 21 CFR 820.100, which of the following is the MOST appropriate initial step in the Corrective and Preventive Action (CAPA) process?
-
A
Implementing a production-wide change to the manufacturing process.
-
B
Disseminating information about the quality problem to all production staff.
-
C
Analyzing all relevant quality data to identify the root cause of the nonconformity.
-
D
Immediately scrapping all affected lots of the device.